Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
126 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rhabdomyosarcoma - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Rhabdomyosarcoma - Pipeline Review, H1 2016', provides an overview of the Rhabdomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma - The report reviews pipeline therapeutics for Rhabdomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Rhabdomyosarcoma therapeutics and enlists all their major and minor projects - The report assesses Rhabdomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Rhabdomyosarcoma Overview 8 Therapeutics Development 9 Pipeline Products for Rhabdomyosarcoma - Overview 9 Pipeline Products for Rhabdomyosarcoma - Comparative Analysis 10 Rhabdomyosarcoma - Therapeutics under Development by Companies 11 Rhabdomyosarcoma - Therapeutics under Investigation by Universities/Institutes 12 Rhabdomyosarcoma - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Rhabdomyosarcoma - Products under Development by Companies 15 Rhabdomyosarcoma - Products under Investigation by Universities/Institutes 16 Rhabdomyosarcoma - Companies Involved in Therapeutics Development 17 Bellicum Pharmaceuticals, Inc. 17 Boehringer Ingelheim GmbH 18 Celgene Corporation 19 EpiZyme, Inc. 20 F. Hoffmann-La Roche Ltd. 21 Merrimack Pharmaceuticals, Inc. 22 Morphotek, Inc. 23 Novartis AG 24 Noxxon Pharma AG 25 Shionogi & Co., Ltd. 26 Rhabdomyosarcoma - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 afatinib dimaleate - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 bevacizumab - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Cellular Immunotherapy for Oncology - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 celyvir - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 everolimus - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 irinotecan hydrochloride - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 NOXS-93 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 ontuxizumab - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 paclitaxel albumin bound - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 pazopanib hydrochloride - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 S-588410 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 tazemetostat - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Rhabdomyosarcoma - Recent Pipeline Updates 82 Rhabdomyosarcoma - Dormant Projects 123 Rhabdomyosarcoma - Discontinued Products 124 Appendix 125 Methodology 125 Coverage 125 Secondary Research 125 Primary Research 125 Expert Panel Validation 125 Contact Us 125 Disclaimer 126
List of Tables
Number of Products under Development for Rhabdomyosarcoma, H1 2016 9 Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 17 Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 18 Rhabdomyosarcoma - Pipeline by Celgene Corporation, H1 2016 19 Rhabdomyosarcoma - Pipeline by EpiZyme, Inc., H1 2016 20 Rhabdomyosarcoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 21 Rhabdomyosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 22 Rhabdomyosarcoma - Pipeline by Morphotek, Inc., H1 2016 23 Rhabdomyosarcoma - Pipeline by Novartis AG, H1 2016 24 Rhabdomyosarcoma - Pipeline by Noxxon Pharma AG, H1 2016 25 Rhabdomyosarcoma - Pipeline by Shionogi & Co., Ltd., H1 2016 26 Assessment by Monotherapy Products, H1 2016 27 Number of Products by Stage and Target, H1 2016 29 Number of Products by Stage and Mechanism of Action, H1 2016 31 Number of Products by Stage and Route of Administration, H1 2016 33 Number of Products by Stage and Molecule Type, H1 2016 35 Rhabdomyosarcoma Therapeutics - Recent Pipeline Updates, H1 2016 82 Rhabdomyosarcoma - Dormant Projects, H1 2016 123 Rhabdomyosarcoma - Discontinued Products, H1 2016 124
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
